Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter double-blind randomized Phase 3 study of denosumab in postmenopausal osteoporosis
2013-001279-19Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of denosumab in osteoporosis (2 arms), sponsored by Amgen. Primary endpoint: Percent change from baseline in lumbar spine BMD at 12 months. Started Jan 2014; status: completed.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2013-001279-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001279-19.